Drug Persistence/Adherence in Patients Being Treated With Dabigatran Etexilate or VKA for Stroke Prevention in Non-valvular Atrial Fibrillation (SPAF)
Active, no longer recruiting
Phase of Trial: Phase IV
Latest Information Update: 25 Jul 2017
At a glance
- Drugs Dabigatran etexilate (Primary) ; Phenprocoumon
- Indications Stroke
- Focus Therapeutic Use
- Acronyms SPAF
- Sponsors Boehringer Ingelheim
- 20 Jul 2017 Planned End Date changed from 1 Dec 2016 to 31 Dec 2017.
- 20 Jul 2017 Planned primary completion date changed from 1 Apr 2016 to 31 Dec 2017.
- 23 Jan 2017 Status changed from recruiting to active, no longer recruiting.